Johnson & Johnson has recalled five of its Neutrogena and Aveeno aerosol spray sunscreens after internal testing uncovered the cancer-causing chemical benzene in some samples. The New Jersey-based company on Wednesday told consumers to immediately stop using the products and discard them. J&J insisted only low levels of benzene were found, which would not be expected to pose a health risk, but said the company was voluntarily recalling the five sunscreens 'out of an abundance of caution.' The affected products are Aveeno Protect + Refresh aerosol sunscreen, and four Neutrogena sunscreen versions: Beach Defense aerosol sunscreen, CoolDry Sport aerosol sunscreen, Invisible Daily Defense aerosol sunscreen and UltraSheer aerosol sunscreen. Johnson & Johnson has recalled five of its Neutrogena and Aveeno aerosol spray sunscreens after internal testing uncovered the cancer-causing chemical benzene in some samples. Aveeno Protect + Refresh aerosol sunscreen (above) is one of the five recalled products The New Jersey-based company on Wednesday told consumers to immediately stop using the products and discard them. The affected products include Beach Defense aerosol sunscreen (left) and UltraSheer aerosol sunscreen (right) CoolDry Sport aerosol sunscreen (left) and Invisible Daily Defense aerosol sunscreen (right) are also among the affected products The recall only impacts sunscreen products packaged in aerosol cans, which were distributed nationwide through retailers. All can sizes and all levels of sun protection factor or SPF are included. J&J is also notifying distributors and retailers to stop selling the products and arranging for their return. Benzene is classified as a human carcinogen, a substance that could potentially cause cancer depending on the level and extent of exposure. It can be inhaled through the airwaves or the skin. J&J said benzene is not an ingredient used in its sunscreen products and it is investigating the cause of the contamination. 'Daily exposure to benzene in these aerosol sunscreen products at the levels detected in our testing would not be expected to cause adverse health consequences,' the company said in a press release announcing the recall. Consumers should contact their physician or healthcare provider if they have any concerns, questions or have experienced any problems related to using these products. The company also said customers can contact its customer care center with any questions and to request a refund and that any adverse reactions from using the products should be reported to the US Food and Drug Administration (FDA). J&J insisted only low levels of benzene were found, which would not be expected to pose a health risk, but said the company was voluntarily recalling the five sunscreens 'out of an abundance of caution.' Pictured the pharma giant's California office J&J said it had notified the FDA of the recall. The recall marks yet another blow for J&J, one of the world's largest producers of consumer health products. The company already faces billions of dollars of potential court losses and settlements from damages claims related to its baby powder, vaginal mesh implants and opioid painkillers. Last month, the US Supreme Court rejected the company's appeal seeking to overturn a verdict ordering it to pay $2.1 billion to women who said its iconic talcum powder products contained asbestos and caused them to develop ovarian cancer. The top court refused to review the case, giving no comment for the justices' decision. The appeal was sent to the court after the Missouri Supreme Court upheld the ruling last year. J&J first faced scrutiny over the safety of its baby powder following an investigative report by Reuters in 2018 that found the company knew for decades that the powder contained asbestos. Last month, the US Supreme Court rejected the company's appeal seeking to overturn a verdict ordering it to pay $2.1 billion to women who said its iconic talcum powder products (above) contained asbestos and caused them to develop ovarian cancer The earliest mention of the chemical in the product was found in documents from 1957 and 1958. The company is now facing more than 21,800 lawsuits against it over the products. In June, J&J also agreed to a $230 million settlement with New York state that bans the company from promoting opioids. The deal allowed the pharma giant to resolve litigation and avoid a trial over its role in the epidemic, while confirming it will stop making or selling opioids in the US. J&J was one of several major pharma firms accused of fueling America's opioid crisis which has killed more than than half a million people since 1999. Meanwhile, the company's COVID-19 vaccine rollout has also been hampered by production problems and the shot has been linked to two very rare side effects: Guillain-Barré Syndrome and a potentially life threatening blood clotting condition. The J&J one-dose vaccine has been linked to clots along with a low platelet-count condition known as thrombocytopenia. The side effect is rare and the company is now looking into whether its vaccine can be modified to reduce the risk. The FDA is planning to release a new warning that the Johnson & Johnson COVID-19 vaccine is linked to a rare autoimmune disease called Guillain-Barré syndrome. Pictured: A member of the Philadelphia Fire Department prepares a dose of the Johnson & Johnson COVID-19 vaccine, March 2021 This week, it emerged the FDA is adding a new warning to the J&J vaccine label due the risk of Guillain-Barré Syndrome. Guillain-Barré Syndrome is a rare autoimmune disorder in which the immune system attacks the peripheral nervous system, temporarily paralyzing parts of the body. The US Centers for Disease Control and Prevention (CDC) said it has received about 100 preliminary reports of Guillain-Barré following the one-dose vaccine Most cases have occurred about two weeks after vaccination and mostly in men aged 50 and older. It is extremely rare with only 100 cases reported out of 12.8 million doses administered. However, such a condition has not been tied to the two other vaccines available in the US - Pfizer and Moderna. US regulators have said that the vaccine's benefits outweigh the risks. All rights reserved for this news site (dailymail) and under his responsibility